Sputum Cytology and Lung Cancer Detection

Sputum cytology is the microscopic examination of cells exfoliated from the airways and expectorated in sputum, used principally to detect and help classify lung cancer. As a non-invasive test it can identify malignant cells, particularly from central tumours that shed cells into the bronchial tree, but its sensitivity is variable and depends heavily on tumour location, specimen quality, and the number of samples examined.

Definition

Sputum cytology is the cytopathologic examination of cells contained in expectorated or induced sputum, performed to detect malignant and other diagnostic cells originating in the lower respiratory tract.

Scope

This topic covers what sputum cytology samples, how specimens are collected and processed, the cytomorphology used to identify malignant cells, the determinants of its diagnostic yield, and its current place relative to bronchoscopic, aspiration, and imaging-based approaches to lung cancer. It is a reference-educational account of the test, not guidance on whom to screen or how to manage findings.

Core questions

• What determines the sensitivity of sputum cytology for lung cancer?
• Which tumours are most and least likely to be detected in sputum?
• How does sputum cytology compare with bronchoscopic and aspiration sampling and with imaging-based detection?

Key concepts

• Expectorated versus induced sputum
• Specimen adequacy and alveolar macrophages as a deep-sample marker
• Central (proximal) versus peripheral tumour shedding
• Effect of specimen number on yield
• Cytomorphology of malignant cells
• Sensitivity-specificity trade-off and false negatives

Mechanisms

Malignant and atypical cells lining or invading the conducting airways are shed into mucus and carried proximally with the mucociliary escalator, becoming available in expectorated sputum. Because central, ulcerating tumours such as squamous cell carcinoma exfoliate readily into large airways, they are more often detected than small peripheral lesions that do not communicate with the bronchial lumen. Yield therefore rises with tumour size and central location, with adequate deep-cough or induced specimens, and with examining multiple sputum samples; conversely poor sampling and peripheral location are major sources of false-negative results (Schreiber 2003; Rivera 2013).

Clinical relevance

Sputum cytology can establish a malignant diagnosis non-invasively in selected patients, especially those with central tumours or who are poor candidates for more invasive procedures, and a positive result is highly specific. Its variable and often modest sensitivity means a negative result does not exclude cancer. This entry describes the test's diagnostic characteristics for reference and does not advise on individual testing or management decisions.

Epidemiology

Reported sensitivity of sputum cytology for lung cancer varies widely across studies and is generally higher for central than peripheral tumours and increases with the number of specimens examined; pooled evidence summarised for clinical guidelines documents this variability and the test's high specificity (Schreiber 2003; Rivera 2013).

Evidence & guidelines

American College of Chest Physicians evidence reviews summarise the diagnostic performance of sputum cytology among modalities for suspected lung cancer (Schreiber 2003; Rivera 2013). For early detection in high-risk populations, randomised evidence established low-dose CT, rather than sputum cytology, as the screening modality shown to reduce lung-cancer mortality (NLST 2011). Tumour categories identified cytologically are framed by the 2021 WHO classification (Nicholson 2022).

History

Examination of sputum for malignant cells dates to early twentieth-century pathology and was advanced by standardised fixation and concentration techniques that improved cellular preservation and yield. Interest in sputum cytology as a screening tool peaked in mid-century lung-cancer screening studies; subsequent randomised trials of low-dose CT reshaped early-detection practice toward imaging (NLST 2011).

Debates

Does sputum cytology have a role in lung cancer screening?

Historical screening programmes using sputum cytology did not demonstrate a mortality benefit, and randomised evidence later established low-dose CT as the screening modality that reduces lung-cancer mortality, leaving sputum cytology a largely diagnostic rather than screening role.

Seminal works

• schreiber-2003
• rivera-2013
• nlst-2011

Frequently asked questions

Why can sputum cytology miss a lung cancer?

Peripheral tumours that do not communicate with the larger airways may shed few or no cells into sputum, and inadequate or too few specimens lower the yield, so a negative sputum cytology does not rule out cancer.

Is a positive sputum cytology reliable?

A confident cytologic diagnosis of malignancy in sputum is highly specific, but interpretation must account for reactive and reparative atypia that can mimic malignancy; correlation with imaging and other specimens is standard.